PARP1 and cancer: The discovery that homologous recombination repair (HRR)-defective breast and ovarian cancers are uniquely sensitive to poly-(ADP-ribose) polymerase (PARP) inhibitors has driven the renewed interest in the design of DDR inhibitors to combat both intrinsic, cancer-specific characteristics and acquired drug resistance [6,7].